Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Massoudi, Marjan, Balk, Mark, Yang, Hongbo, Bui, Cat N., Pandya, Bhavik J., Guo, Jenny, Song, Yan, Wu, Eric Q., Brown, Bruce, Barlev, Arie, Flanders, ScottLanguage:
english
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2016.1229670
Date:
August, 2016
File:
PDF, 829 KB
english, 2016